MannKind Corp, Q3 2026 Earnings Call Transcript

MannKind expects record fourth-quarter revenue to return the company to GAAP and non-GAAP profitability, with annual profitability anticipated in 2027 as it continues investing in growth. Furoscix ReadyFlow adoption has exceeded expectations, and management expects fourth-quarter sales to match the first half of 2026; lower production costs should support margin improvement. Afrezza’s pediatric launch is driving prescription growth, while the company plans to rebuild its adult business through increased promotional focus. Tyvaso DPI royalties provide recurring cash flow, and MannKind expects more than $1 billion in revenue from its United Therapeutics agreement from 2027 through 2030. Its nintedanib DPI Phase II trial is underway, with results expected in the first half of 2028; the company also sees potential in ralinepag DPI and other product enhancements.